A multi-target protein of hTERTR-FAM96A presents significant anticancer potent in the treatment of hepatocellular carcinoma

Tumor Biology

Volumn 39, Issue 4, 2017, Pages

  Zhang, Meng Yu ^a   Wang, Jie Ping ^a  

^a THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Apaf 1; apoptosis; hepatocellular carcinoma; hTERT; hTERTR FAM96A; tumor therapy

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; GAMMA INTERFERON; HTERTR FAM96A; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; CARRIER PROTEIN; FAM96A PROTEIN, HUMAN; ONCOPROTEIN; TELOMERASE; TERT PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CELLULAR IMMUNITY; CLINICAL OUTCOME; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; DRUG PROTEIN BINDING; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNOLOGY; UPREGULATION; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETICS; LIVER NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MICE; ONCOGENE PROTEINS, FUSION; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020170069     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317698341     Document Type: Article

References (33)

1. Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma—a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014; 40: 893–902.
2. Shariff MI, Cox IJ, Gomaa AI. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009; 3: 353–367.
3. Simonetti RG, Camma C, Fiorello F. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991; 36: 962–972.
4. Zidan A, Scheuerlein H, Schule S. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in Iran and worldwide. Hepat Mon 2012; 12: e6894.
5. Guo Z, Yu H, Liu C. Advances in endovascular therapy to treat primary hepatocellular carcinoma. Drug Discov Ther 2015; 9: 342–351.
6. Jiang J, Yu C, Chen M. Over-expression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/beta-catenin signaling. Biochem Biophys Res Commun 2015; 464: 1120–1127.
7. Mizukoshi E, Nakagawa H, Kitahara M. Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. Cancer Lett 2015; 369: 242–249.
8. Ibrahim AA, Abdel Aleem MH, Abdella HM. Study of the role of insulin resistance as a risk factor in HCV related hepatocellular carcinoma. J Egypt Soc Parasitol 2015; 45: 107–113.
9. Monian P, Jiang X. The cellular apoptosis susceptibility protein (CAS) promotes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis and cell proliferation. J Biol Chem 2016; 291: 2379–2388.
10. Park YJ, Kim EK, Bae JY. Human telomerase reverse transcriptase (hTERT) promotes cancer invasion by modulating cathepsin D via early growth response (EGR)-1. Cancer Lett 2016; 370: 222–231.
11. Abdul-Ghani R, Ohana P, Matouk I. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2000; 2: 539–544.
12. He L, Gong HX, Li XP. Inhibition of hepatocellular carcinoma growth by adenovirus-mediated expression of human telomerase reverse transcriptase COOH-27 terminal polypeptide in mice. Oncol Lett 2013; 6: 748–752.
13. Huang JJ, Lin MC, Bai YX. Ectopic expression of a COOH-terminal fragment of the human telomerase reverse transcriptase leads to telomere dysfunction and reduction of growth and tumorigenicity in HeLa cells. Cancer Res 2002; 62: 3226–3232.
14. Stehling O, Mascarenhas J, Vashisht AA. Human CIA2A-FAM96A and CIA2B-FAM96B integrate iron homeostasis and maturation of different subsets of cytosolic-nuclear iron-sulfur proteins. Cell Metab 2013; 18: 187–198.
15. Mas C, Chen KE, Brereton IM. Backbone resonance assignments of the monomeric DUF59 domain of human Fam96a. Biomol NMR Assign 2013; 7: 117–120.
16. Chen KE, Richards AA, Ariffin JK. The mammalian DUF59 protein Fam96a forms two distinct types of domain-swapped dimer. Acta Crystallogr D Biol Crystallogr 2012; 68: 637–648.
17. Schwamb B, Pick R, Fernandez SB. FAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors. Int J Cancer 2015; 137: 1318–1329.
18. Ouyang B, Wang L, Wan S. Solution structure of monomeric human FAM96A. J Biomol NMR 2013; 56: 387–392.
19. Ghothim M, Srovnal J, Bebarova L. [Determination of CEA, EGFR and hTERT expression in peritoneal lavage in patients with pancreatic adenocarcinoma using RT-PCR method]. Rozhl Chir 2015; 94: 464–469, discussion 469.
20. Hons JM. New Insights into the immunomodulatory effects of exercise and potential impact on tumorigenesis. Oncology 2015; 29: 214802.
21. Aldinucci D, Celegato M, Casagrande N. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance. Cancer Lett 2015; 380(1): 243–252.
22. Xu H, Gong X, Zhang HH. Targeting human telomerase reverse transcriptase by a simple siRNA expression cassette in HepG2 cells. Hepat Mon 2015; 15: e24343.
23. de Martino M, Taus C, Lucca I. Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology. Mol Carcinog 2016; 55: 1458–1466.
24. Fleisig HB, Hukezalie KR, Thompson CA. Telomerase reverse transcriptase expression protects transformed human cells against DNA-damaging agents, and increases tolerance to chromosomal instability. Oncogene 2016; 35: 218–227.
25. Sacco PC, Maione P, Rossi A. Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. Target Oncol 2011; 6: 171–180.
26. Batist G, Wu JH, Spatz A. Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. Front Pharmacol 2011; 2: 59.
27. Aggarwal R, Ryan CJ. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist 2011; 16: 264–275.
28. Rivera F, Lopez-Tarruella S, Vega-Villegas ME. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 2009; 35: 335–339.
29. Bunn PA, Jr Kelly K. Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer. Clin Lung Cancer 2000; 2(Suppl. 1): S23–S28.
30. Cabrespine A, Bay JO, Barthomeuf C. In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment. Anticancer Drugs 2005; 16: 417–422.
31. Lee BS, Kim HJ, Hwang JW. The dual inhibition of Met and EGFR by ME22S, a novel Met/EGFR bispecific monoclonal antibody, suppresses the proliferation and invasion of laryngeal cancer. Ann Surg Oncol 2016; 23(6): 2046–2053.
32. Taki S, Kamada H, Inoue M. A novel bispecific antibody against human CD3 and ephrin receptor A10 for breast cancer therapy. PLoS One 2015; 10: e0144712.
33. Baghaei A, Solgi R, Jafari A. Molecular and biochemical evidence on the protection of cardiomyocytes from phosphine-induced oxidative stress, mitochondrial dysfunction and apoptosis by acetyl-l-carnitine. Environ Toxicol Pharmacol 2016; 42: 30–37.